Astellas Pharma Inc. - ADR

Astellas Pharma Inc. - ADR

ALPMY

Get informed when a big investor buys or sells

+ Follow
Market Cap$26.97B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Astellas Pharma Inc. - ADRAstellas Pharma Inc. - ADR11.73.27%16%-0.3
$48.53

Current Fair Value

220.4% upside

Undervalued by 220.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$26.97 Billion
Enterprise Value$369.86 Billion
Dividend Yield$0.46 (3.27%)
Earnings per Share$172.56
Beta0.09
Outstanding Shares1,791,933,000

Return

Return on Equity15.76%ROE
Return on Assets8.29%
Return on Invested Capital17.25%

Valuation & Multiples

P/E Ratio11.72P/E Ratio
PEG10.67PEG
Price to Sales0.01Price to Sales
Price to Book Ratio0.01Price to Book Ratio
Enterprise Value to Revenue0.2
Enterprise Value to EBIT0.88
Enterprise Value to Net Income1
Total Debt to Enterprise1.58
Debt to Equity0.3Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 5, 2026
EPS Estimate
$0.34
Average shareholder expectation
Revenue Estimate
$3.47 B
Average shareholder expectation

Next Earnings Call

Expected Date
October 29, 2026
EPS Estimate
$0.39
Average shareholder expectation
Revenue Estimate
$3.66 B
Average shareholder expectation

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

ESG Score

No data

About Astellas Pharma Inc.

CEO: Kenji Yasukawa